No Data
On November 28, He Bo Pharmaceutical-B (02142.HK) spent 0.071 million HKD to repurchase 0.06 million shares.
Glory Capital announced on November 28 that Heber Medical-B (02142.HK) repurchased 0.06 million shares on November 28, 2024, at a cost of 0.071 million Hong Kong dollars, with a repurchase price of 1.18-1.19 Hong Kong dollars per share.
Heptagon Pharmaceuticals-B (02142.HK) spent HKD 0.2404 million to repurchase 0.2 million shares on November 25.
Gelonghui, November 25th丨Hepalink Pharmaceutical-B (02142.HK) announced that on November 25, 2024, it spent 0.2404 million HKD to repurchase 0.2 million shares, with a repurchase price of 1.19-1.21 HKD per share.
On November 22, Huabo Pharmaceuticals-B (02142.HK) spent 0.244 million Hong Kong dollars to repurchase 0.2 million shares.
On November 22, Gelonghui announced that Heber Pharmaceuticals-B (02142.HK) spent 0.244 million Hong Kong dollars to repurchase 0.2 million shares.
Express News | Harbour Biomed Appoints DR. Raymond Zheng as Chief Business Officer
Pharmaceutical announced the appointment of Dr. Zheng Lei as Chief Commercial Officer.
On November 15, 2024, in Suzhou, China, Cambridge, Massachusetts, usa, and Rotterdam, Netherlands / PRNewswire / - HuaBo Pharmaceutical (stock code: 02142.HK), a global biomedical company specializing in innovative antibody therapy discovery, development, and commercialization in the fields of oncology and immunology, today formally appointed Dr. Zheng Lei as Chief Business Officer (CBO). Dr. Zheng will be based in the usa and will be responsible for the company's global business expansion and asset management, reporting directly to Dr. Wang Jinsong, founder, chairman, and CEO of HuaBo Pharmaceutical. During his tenure as Chief Business Officer, Dr. Zheng will effectively
Press Release: Harbour BioMed Appoints Dr. Raymond Zheng as Chief Business Officer
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
